Peter Andersen

We are pleased with the positive news. This mutation is mainly found in young ALS patients, and in them, the disease often has a very rapid progression. The new drug showed stabilization and a halt to further disease progression in several patients, says Peter Andersen, who is a professor of neurology at the Department of Clinical Science at Umeå University and responsible for the study at Norrlands University Hospital. The lesson from our research is that we need to understand the processes that lead to nerve cell death in ALS in order to develop effective medications. Here, Sweden has made a strong contribution, with several families participating in the research and three Swedish patients donating their bodies to medical research specifically on FUS-ALS, says Peter Andersen. (translated)